Agios Pharmaceuticals (NASDAQ:AGIO) had its price target increased by Needham & Company LLC from $72.00 to $86.00 in a research report report published on Thursday, February 15th, Marketbeat reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock.
AGIO has been the topic of several other research reports. Credit Suisse Group increased their price target on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an outperform rating in a research report on Thursday, November 2nd. Oppenheimer cut shares of Agios Pharmaceuticals from an outperform rating to a market perform rating in a research report on Wednesday, February 14th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Agios Pharmaceuticals from a hold rating to a buy rating and set a $84.00 price target on the stock in a research report on Tuesday, January 16th. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, December 12th. Finally, ValuEngine raised shares of Agios Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, February 2nd. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $85.50.
Shares of Agios Pharmaceuticals (AGIO) opened at $84.52 on Thursday. The stock has a market cap of $4,840.00, a PE ratio of -12.54 and a beta of 2.02. Agios Pharmaceuticals has a 1 year low of $45.11 and a 1 year high of $85.88.
In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 53,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the sale, the chief executive officer now owns 53,000 shares of the company’s stock, valued at $3,877,480. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $65.00, for a total transaction of $195,000.00. Following the sale, the insider now directly owns 56,059 shares in the company, valued at approximately $3,643,835. The disclosure for this sale can be found here. In the last ninety days, insiders sold 191,180 shares of company stock worth $14,758,309. 5.43% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the business. QS Investors LLC acquired a new stake in Agios Pharmaceuticals during the second quarter worth approximately $144,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Agios Pharmaceuticals by 41.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 762 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth approximately $160,000. Cubist Systematic Strategies LLC raised its holdings in Agios Pharmaceuticals by 1,041.0% during the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 3,123 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 1,520 shares in the last quarter. 82.40% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://stocknewstimes.com/2018/03/13/needham-company-llc-boosts-agios-pharmaceuticals-agio-price-target-to-86-00.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.